Navigation Links
New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies
Date:11/12/2009

MINNEAPOLIS/ST. PAUL, Nov. 12 /PRNewswire/ -- New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods. Susan Sencer, MD, Medical Director, Hematology/Oncology at Children's Hospitals and Clinics of Minnesota (Children's), presented findings on the use of the homeopathic agent Traumeel S® in children with mucositis undergoing stem cell transplantation (SCT). Investigated by the Children's Oncology Group, the multi-center randomized placebo controlled trial is the first large-scale pediatric oncology trial of a CAM treatment.

Mucositis is a painful side effect of many cancer treatment regimens. Mucositis can cause intense pain, infection and the inability to eat, drink or swallow, and there are few known treatments for the condition. A small pilot study of the homeopathic agent Traumeel S® had previously shown promise in treating and preventing this serious complication of cancer therapy. Results of the current larger study did not confirm the earlier study, but showed the potential for CAM therapies to be evaluated using the same methodology as other medical treatments. Mainstream medicine relies upon conventional, validated research methods such as the randomized, blinded controlled trial to help guide clinical practice; CAM methods have not always been easily evaluated with these techniques, contributing to CAM's lack of acceptance by many physicians.

"We know complementary treatments can be very helpful for pediatric patients, but there is limited research to support our clinical observations," said Dr. Sencer. "While we found this treatment to be ineffective for mucositis, I'm excited about the potential this trial has for the future of complementary and alternative medicine research."

The 190 eligible patients in the trial received either Traumeel S® or a placebo five times daily as a swish and swallow rinse for the treatment. Results showed Traumeel S® to be ineffective at preventing and treating mucositis in SCT patients. No adverse events were found to be related to use of the study drug.

At Children's, CAM is often used in pediatric oncology patients to reduce pain, discomfort and other side-effects associated with treating cancer. The Hematology/Oncology Program at Children's is the largest in the upper Midwest with treatment outcomes that consistently rank Children's as one of the top ten programs in the U.S. The Integrative Medicine Program at Children's, which combines the best of complementary and conventional medical therapies, is the largest, longest-running pediatric, clinical integrative medicine program in North America.

About Children's Hospitals and Clinics of Minnesota

Serving as Minnesota's children's hospital since 1924, Children's Hospitals and Clinics of Minnesota is the seventh-largest pediatric health care organization in the United States, with 332 staffed beds at its two hospitals in St. Paul and Minneapolis. An independent, not-for-profit health care system, Children's of Minnesota provides care through more than 14,000 inpatient visits and more than 200,000 emergency room and other outpatient visits every year. Children's is the only Minnesota hospital system to provide comprehensive care exclusively to children. For more information, visit www.childrensmn.org.

SOURCE Children's Hospitals and Clinics of Minnesota


'/>"/>
SOURCE Children's Hospitals and Clinics of Minnesota
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... As health professionals work to improve their approach to healthcare, ... doing more than filling out a survey; in many cases health professionals and patients ... health care and research on the importance of active engagement with patients and members ...
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
Breaking Medicine News(10 mins):